Aggregate milestone payments.

No definition available.

Name:	pyxs_AggregateMilestonePayments
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Annual license maintenance fees.

+ References

No definition available.

+ Details

Name:	pyxs_AnnualLicenseMaintenanceFees
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Convertible preferred stock shares issued value.

+ References

No definition available.

+ Details

Name:	pyxs_ConvertiblePreferredStockSharesIssuedValue
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Extra milestone payment.

+ References

No definition available.

+ Details

Name:	pyxs_ExtraMilestonePayment
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Issuance of convertible preferred stock shares.

+ References

No definition available.

+ Details

Name:	pyxs_IssuanceOfConvertiblePreferredStockShares
Namespace Prefix:	pyxs_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone and royalties incurred.

+ References

No definition available.

+ Details

Name:	pyxs_MilestoneAndRoyaltiesIncurred
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payments payable upon certain achievements.

+ References

No definition available.

+ Details

Name:	pyxs_MilestonePaymentsPayableUponCertainAchievements
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum annual royalty fees.

+ References

No definition available.

+ Details

Name:	pyxs_MinimumAnnualRoyaltyFees
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

One-time milestone payment.

+ References

No definition available.

+ Details

Name:	pyxs_OneTimeMilestonePayment
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment for license fee.

+ References

No definition available.

+ Details

Name:	pyxs_PaymentForLicenseFee
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential development and commercial milestone payment.

+ References

No definition available.

+ Details

Name:	pyxs_PotentialDevelopmentAndCommercialMilestonePayment
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research and development licensed product estimated cost.

+ References

No definition available.

+ Details

Name:	pyxs_ResearchAndDevelopmentLicensedProductEstimatedCost
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Royalty obligation period for licensed products upon first commercial sale.

+ References

No definition available.

+ Details

Name:	pyxs_RoyaltyObligationPeriodForLicensedProductsUponFirstCommercialSale
Namespace Prefix:	pyxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Sublicensing revenue percentage.

+ References

No definition available.

+ Details

Name:	pyxs_SublicensingRevenuePercentage
Namespace Prefix:	pyxs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront payments.

+ References

No definition available.

+ Details

Name:	pyxs_UpfrontPayments
Namespace Prefix:	pyxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

+ Details

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313

+ Details

Name:	us-gaap_DerivativeLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash inflow from exercise of option under share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromStockOptionsExercised
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=pyxs_LegoChemLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pyxs_UniversityLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Additional Information (Details) - USD ($)	1 Months Ended				12 Months Ended
	Apr. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Apr. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expense					$ 51,054,000	$ 9,048,000
Proceeds from stock options exercised					167,000	32,000
Accounts payable			$ 1,077,000		11,951,000	$ 1,077,000
Pfizer License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expense					25,000,000.0
Royalty obligation period for licensed products upon first commercial sale			12 years
Milestone and royalties required					0
Upfront payments					5,000,000.0
Sublicensing revenue percentage			30.00%			30.00%
One-time payment					0
Pfizer License Agreement \| Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payment for license fee					$ 25,000,000.0
Pfizer License Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Aggregate milestone payments for first four licensed products			$ 660,000,000
One-time payment			$ 20,000,000.0			$ 20,000,000.0
Pfizer License Agreement \| Series B Convertible Preferred Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Issuance of convertible preferred stock shares					12,152,145
Issuance of convertible preferred stock value					$ 20,000,000.0
LegoChem License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and development expense					0
Royalty obligation period for licensed products upon first commercial sale			10 years
Milestone and royalties required			$ 0		0	0
Upfront payments		$ 500,000				5,000,000.0
Payments to purchase licensed products			500,000		9,000,000.0
Licensed product estimated cost			7,000,000.0			7,000,000.0
Proceeds from stock options exercised	$ 8,000,000.0
Extra Milestone Payment				$ 9,600,000
Accounts payable					9,600,000
Derivative liability							$ 3,400,000
LegoChem License Agreement \| Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payments					9,000,000.0	500,000
LegoChem License Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments payable upon certain achievements			284,500,000
LegoChem License Agreement \| Series B Convertible Preferred Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Issuance of convertible preferred stock shares		303,804
University License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Stock issued				48,919
Research and development expense					0	3,000
Annual maintenance fee				$ 10,000
Royalty obligation period for licensed products upon first commercial sale				10 years
Milestone and royalties required			$ 0		$ 0	$ 0
University License Agreement \| Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential development and commercial milestones				$ 7,700,000
Minimum annual royalty fees				$ 3,000,000.0